Literature DB >> 17911267

Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.

Jiangbing Zhou1, Julia Wulfkuhle, Hao Zhang, Peihua Gu, Yanqin Yang, Jianghong Deng, Joseph B Margolick, Lance A Liotta, Emanuel Petricoin, Ying Zhang.   

Abstract

Side-population (SP) cells within cancers and cell lines are rare cell populations known to enrich cancer stem-like cells. In this study, we characterized SP cells from the human breast cancer cell line MCF7 as a model for cancer stem-like cells. Compared with non-SP cells, MCF7 SP cells had higher colony-formation ability in vitro and greater tumorigenicity in vivo, suggesting that MCF7 SP cells enrich cancer stem-like cells. cDNA microarray analysis of the SP cells indicated higher expression of ATP-binding cassette transporters and genes involved in quiescence, which were confirmed by quantitative RT-PCR and flow cytometry cell cycle analysis. To identify signal pathways important for cancer stem-like cells, we analyzed cDNA microarray data and identified nine pathways that were altered in the SP cells. To analyze the protein signaling networks, we used reverse-phase signaling pathway protein microarray technology and identified three signaling proteins that are significantly different between MCF7 SP and non-SP cells. Notably, signaling of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), signal transduction and activator of transcription (STAT3), and phosphatase and tensin homolog (PTEN) was confirmed to be critical for MCF7 SP cell survival and proliferation by pathway specific inhibitors, selected gene knockdown, and in vivo tumorigenicity assay. The STAT3 pathway was found to be positively regulated by mTOR signaling, whereas PTEN served as a negative regulator of both STAT3 and mTOR signaling. This study suggests the existence of prosurvival signaling pathways critical for cancer stem-like cell maintenance, which could be selectively targeted for inhibiting cancer stem-like cells for improved treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911267      PMCID: PMC2042178          DOI: 10.1073/pnas.0702596104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

Review 2.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

3.  Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends.

Authors:  H L Howe; P A Wingo; M J Thun; L A Ries; H M Rosenberg; E G Feigal; B K Edwards
Journal:  J Natl Cancer Inst       Date:  2001-06-06       Impact factor: 13.506

4.  Survival of acute myeloid leukemia cells requires PI3 kinase activation.

Authors:  Qing Xu; Serge-Emile Simpson; Timothy J Scialla; Adam Bagg; Martin Carroll
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

5.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front.

Authors:  C P Paweletz; L Charboneau; V E Bichsel; N L Simone; T Chen; J W Gillespie; M R Emmert-Buck; M J Roth; E F Petricoin III; L A Liotta
Journal:  Oncogene       Date:  2001-04-12       Impact factor: 9.867

6.  Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR.

Authors:  K Yokogami; S Wakisaka; J Avruch; S A Reeves
Journal:  Curr Biol       Date:  2000-01-13       Impact factor: 10.834

7.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.

Authors:  S Zhou; J D Schuetz; K D Bunting; A M Colapietro; J Sampath; J J Morris; I Lagutina; G C Grosveld; M Osawa; H Nakauchi; B P Sorrentino
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

8.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

9.  Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays.

Authors:  Julia D Wulfkuhle; Joy A Aquino; Valerie S Calvert; David A Fishman; George Coukos; Lance A Liotta; Emanuel F Petricoin
Journal:  Proteomics       Date:  2003-11       Impact factor: 3.984

10.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

View more
  291 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  IQGAP1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation by Akt activation.

Authors:  Feng Chen; Hai Hong Zhu; Lin Fu Zhou; Shan Shan Wu; Jing Wang; Zhi Chen
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

3.  Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype.

Authors:  Kaijie He; Tong Xu; Amir Goldkorn
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

4.  Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion.

Authors:  Utpal K Mukhopadhyay; Patrick Mooney; Lilly Jia; Robert Eves; Leda Raptis; Alan S Mak
Journal:  Mol Cell Biol       Date:  2010-08-23       Impact factor: 4.272

Review 5.  Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells.

Authors:  Gaoliang Ouyang; Zhe Wang; Xiaoguang Fang; Jia Liu; Chaoyong James Yang
Journal:  Cell Mol Life Sci       Date:  2010-03-18       Impact factor: 9.261

Review 6.  Cancer stem cells and their role in metastasis.

Authors:  Yusuke Shiozawa; Biao Nie; Kenneth J Pienta; Todd M Morgan; Russell S Taichman
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

7.  Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.

Authors:  Rehan Akbani; Karl-Friedrich Becker; Neil Carragher; Ted Goldstein; Leanne de Koning; Ulrike Korf; Lance Liotta; Gordon B Mills; Satoshi S Nishizuka; Michael Pawlak; Emanuel F Petricoin; Harvey B Pollard; Bryan Serrels; Jingchun Zhu
Journal:  Mol Cell Proteomics       Date:  2014-04-28       Impact factor: 5.911

8.  Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.

Authors:  Yan Zhou; Jiyuan Yang; Rui Zhang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2014-12-03       Impact factor: 5.571

9.  Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth.

Authors:  Triparna Ghosh-Choudhury; Chandi C Mandal; Kathleen Woodruff; Patricia St Clair; Gabriel Fernandes; Goutam G Choudhury; Nandini Ghosh-Choudhury
Journal:  Breast Cancer Res Treat       Date:  2008-10-26       Impact factor: 4.872

10.  Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.

Authors:  P-P Liu; J Liao; Z-J Tang; W-J Wu; J Yang; Z-L Zeng; Y Hu; P Wang; H-Q Ju; R-H Xu; P Huang
Journal:  Cell Death Differ       Date:  2013-10-04       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.